Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer, Ocular, Ocular |
| Therapuetic Areas: | Oncology, Ophthalmology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 3/27/2019 |
| Start Date: | May 23, 2018 |
| End Date: | March 21, 2019 |
Age-Related Eye Disease Study 2 (AREDS2) 10-Year Follow-On Study
Background:
Age-related macular degeneration (AMD) and cataracts are two eye diseases. They were studied
in the Age-Related Eye Disease Study (AREDS2) and the AREDS2 Follow-On study. These studies
followed the natural course of the diseases. They also provided data on the long-term effects
of certain oral supplements on AMD.
Objective:
To study the long-term effects of oral supplements on several things. These include
incidences of lung cancer, development of late AMD, cataract surgery, cognitive function, and
cardiovascular events.
Eligibility:
Former AREDS2 and AREDS2 Follow-On participants
Design:
Participants will have 1 visit. It will include:
An eye exam that tests how well participants can see, measures eye pressure, and checks eye
movements. The pupil will be dilated with eye drops. Pictures will be taken of the retina and
the inside of the eye.
Participants will grip a device in their hand to measure their grip strength.
A blood sample will be taken. This will be stored for future genetic research. Cells may be
created from the sample.
A small sample of skin will be taken.
Sponsoring Institution: National Eye Institute
Age-related macular degeneration (AMD) and cataracts are two eye diseases. They were studied
in the Age-Related Eye Disease Study (AREDS2) and the AREDS2 Follow-On study. These studies
followed the natural course of the diseases. They also provided data on the long-term effects
of certain oral supplements on AMD.
Objective:
To study the long-term effects of oral supplements on several things. These include
incidences of lung cancer, development of late AMD, cataract surgery, cognitive function, and
cardiovascular events.
Eligibility:
Former AREDS2 and AREDS2 Follow-On participants
Design:
Participants will have 1 visit. It will include:
An eye exam that tests how well participants can see, measures eye pressure, and checks eye
movements. The pupil will be dilated with eye drops. Pictures will be taken of the retina and
the inside of the eye.
Participants will grip a device in their hand to measure their grip strength.
A blood sample will be taken. This will be stored for future genetic research. Cells may be
created from the sample.
A small sample of skin will be taken.
Sponsoring Institution: National Eye Institute
Objective: The overall objective of this extended follow-up study is to provide data
regarding the incidence of late age-related macular degeneration (AMD), cataract surgery and
lung cancer in the approximately 1,200 AREDS2 study participants enrolled in the Follow-on
study. The specific objectives for the study are to:
- Study the rates of progression to late AMD, neovascular AMD, or geographic atrophy
associated with AMD.
- To seek incidences of lung cancer, by treatment assignment.
- To assess cognitive understanding by phone prior to coming into the clinic.
- To seek incidences of cardiovascular events.
Study Population: Up to 3,200 participants who were previously enrolled in the AREDS2 and
AREDS2 Follow-on protocols are currently followed by telephone contact every six months for
the past four years. It is expected that 1,200 of these 3,200 participants will be eligible
to participate in the study. Up to 83 participants will be enrolled at the NEI.
Design: This is an extension of the multicenter, randomized trial of lutein, zeaxanthin and
omega-3 polyunsaturated fatty acids in the AMD AREDS2 trial. Data for this extension will be
collected by staff at selected AREDS2 clinical sites via an in-clinic visit.
Outcome Measures: The primary outcomes of the study will be the rates of progression to late
AMD, neovascular AMD or geographic atrophy associated with AMD. Also of interest are the
long-term rates of progression to late AMD, incidents of lung cancer and cataract surgery.
Participant reports of incident cardiovascular events will be collected as secondary
outcomes.
regarding the incidence of late age-related macular degeneration (AMD), cataract surgery and
lung cancer in the approximately 1,200 AREDS2 study participants enrolled in the Follow-on
study. The specific objectives for the study are to:
- Study the rates of progression to late AMD, neovascular AMD, or geographic atrophy
associated with AMD.
- To seek incidences of lung cancer, by treatment assignment.
- To assess cognitive understanding by phone prior to coming into the clinic.
- To seek incidences of cardiovascular events.
Study Population: Up to 3,200 participants who were previously enrolled in the AREDS2 and
AREDS2 Follow-on protocols are currently followed by telephone contact every six months for
the past four years. It is expected that 1,200 of these 3,200 participants will be eligible
to participate in the study. Up to 83 participants will be enrolled at the NEI.
Design: This is an extension of the multicenter, randomized trial of lutein, zeaxanthin and
omega-3 polyunsaturated fatty acids in the AMD AREDS2 trial. Data for this extension will be
collected by staff at selected AREDS2 clinical sites via an in-clinic visit.
Outcome Measures: The primary outcomes of the study will be the rates of progression to late
AMD, neovascular AMD or geographic atrophy associated with AMD. Also of interest are the
long-term rates of progression to late AMD, incidents of lung cancer and cataract surgery.
Participant reports of incident cardiovascular events will be collected as secondary
outcomes.
- INCLUSION CRITERIA:
To participate in this study, the potential participant must meet all of the following
criteria:
1. Previously enrolled in the AREDS2 and AREDS2 Follow-on protocols.
2. Participant must be offered sufficient opportunity to review and to understand the
informed consent form, agree to the form s contents and provide written informed
consent.
EXCLUSION CRITERIA:
There are no Exclusion Criteria.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
301-496-2563
Phone: 800-411-1222
National Institutes of Health Clinical Center The National Institutes of Health (NIH) Clinical Center in...
Click here to add this to my saved trials
